$SRPT News

Sarepta Faces Competitive Pressures Despite Pipeline Updates, RBC Says

Sarepta Therapeutics Inc (SRPT) (Q2 2026) Earnings Call Highlights: Strong Profitability and ...

Sarepta Therapeutics Q2 Earnings Call Highlights

Sarepta Therapeutics (NASDAQ:SRPT) Surges on Q2 Earnings Beat and Narrowed Outlook

Sarepta Therapeutics, Inc. Q2 2026 Earnings Call Summary

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics

Sarepta Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Sarepta Therapeutics Q2 Adj. EPS $0.64 Beats $0.26 Estimate, Sales $401.300M Beat $364.343M Estimate

Sarepta Therapeutics (SRPT) Names A New CEO, Is The Stock Cheap?

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Earnings Preview: Sarepta Therapeutics (SRPT) Q2 Earnings Expected to Decline

Leadership changes afoot at two CGT biotechs

Morgan Stanley Views Sarepta CEO Transition As A ‘Positive’ – So, Why Is It Cautious On SRPT Stock In The Near Term?

Sarepta Therapeutics Appoints Michael Severino CEO, Effective July 28, Succeeding Doug Ingram

SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?

Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results

SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space